drugset / Trial / NCT04795141
ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing spondylitis(AS). The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 16 in subjects with active AS.
Timeline
- Start
- 2021-08-24
- Primary completion
- 2022-07-11
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izokibep | Protein / enzyme biologic | — | Subcutaneous |